Lung Disease News and Research RSS Feed - Lung Disease News and Research

NIH-funded clinical trial aims to restore vision in people who have lost vision due to IIH

NIH-funded clinical trial aims to restore vision in people who have lost vision due to IIH

In an NIH-funded clinical trial, led at Saint Louis University by professor of ophthalmology Sophia Chung, M.D., researchers aim to bring sight back to those who have lost vision due to idiopathic intracranial hypertension. [More]
Lung cancer clinical trials exclude substantial proportion of patients due to prior cancer

Lung cancer clinical trials exclude substantial proportion of patients due to prior cancer

Lung cancer clinical trials exclude a substantial proportion of patients due to a history of prior cancer, as shown in an analysis by cancer researchers at UT Southwestern Medical Center. [More]
FDG-PET technology less accurate in diagnosing lung cancer in regions where infections are common

FDG-PET technology less accurate in diagnosing lung cancer in regions where infections are common

A new analysis of published studies found that FDG-PET technology is less accurate in diagnosing lung cancer versus benign disease in regions where infections like histoplasmosis or tuberculosis are common. Misdiagnosis of lung lesions suspicious for cancer could lead to unnecessary tests and surgeries for patients, with additional potential complications and mortality. [More]
Pneumonia in COPD patients has distinct clinical features

Pneumonia in COPD patients has distinct clinical features

The aetiology and clinical features of community-acquired pneumonia are different in people with chronic obstructive pulmonary disease than in those without the lung condition, Spanish research demonstrates. [More]
SLU pediatric researcher to study efficacy of new hepatitis C drug treatment in children

SLU pediatric researcher to study efficacy of new hepatitis C drug treatment in children

After the success of a new drug treatment in adults with hepatitis C infection, a Saint Louis University pediatric researcher is testing the safety and efficacy of the medications in children. [More]
Novel virus could be source of severe respiratory disease in ball pythons

Novel virus could be source of severe respiratory disease in ball pythons

Researchers have identified a novel virus that could be the source of a severe, sometimes fatal respiratory disease that has been observed in captive ball pythons since the 1990s. The work is published this week in mBio-, the online open-access journal of the American Society for Microbiology. [More]
SLU researchers work to prevent several serious infectious diseases

SLU researchers work to prevent several serious infectious diseases

Saint Louis University researchers are attacking influenza on multiple fronts as they search for a universal vaccine that protects people from the flu virus that often mutates year to year with deadly consequences. [More]
Birth weight measurements can be used to predict lung function during late teenage years

Birth weight measurements can be used to predict lung function during late teenage years

A new study has found that factors, such as birth weight, gestational age at birth and lung function, growth and other measures at 8 years, can be used to predict lung function during mid to late teenage years. [More]

Researchers suggest that proportion of IPF may be due to unknown exposure to asbestos

A proportion of idiopathic pulmonary fibrosis cases may be linked with asbestos exposure, according to the results of a new study. [More]
Ornamental birds and exposure to pigeons may contribute to hypersensitive pneumonitis

Ornamental birds and exposure to pigeons may contribute to hypersensitive pneumonitis

Ornamental birds and feather pillows, plus daily exposure to pigeons may contribute to the development hypersensitive pneumonitis, a disease that can cause irreversible damage to the lungs. [More]
LSDF announces $750,000 in Proof of Concept grants to promote health-related technologies

LSDF announces $750,000 in Proof of Concept grants to promote health-related technologies

The Life Sciences Discovery Fund (LSDF) today announced nearly $750,000 in Proof of Concept grants to Washington state for-profit and non-profit organizations to promote translation of health-related technologies from the laboratory to the commercial marketplace. [More]
Accreditation of bariatric surgery centers contributes to improved safety for patients

Accreditation of bariatric surgery centers contributes to improved safety for patients

Patients who underwent weight loss operations in recent years, when most bariatric surgical centers were accredited, had fewer postoperative complications and were 2.3 times less likely to die in the hospital than patients who had bariatric procedures performed before a national movement toward facility accreditation was taking place, according to new study findings. [More]
Study finds 1/4 of errors made in medical publications

Study finds 1/4 of errors made in medical publications

A new Saint Louis University study finds one fourth of errors made in medical publications can change the way data are interpreted. [More]
New UCLA study finds that oxidized lipids may also contribute to pulmonary hypertension

New UCLA study finds that oxidized lipids may also contribute to pulmonary hypertension

Oxidized lipids are known to play a key role in inflaming blood vessels and hardening arteries, which causes diseases like atherosclerosis. A new study at UCLA demonstrates that they may also contribute to pulmonary hypertension, a serious lung disease that narrows the small blood vessels in the lungs. [More]
Sorrento receives funding to advance immunotherapy targeting WISP1 for treatment of IPF

Sorrento receives funding to advance immunotherapy targeting WISP1 for treatment of IPF

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that it has received funding to advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) for the potential treatment of IPF, which affects more than 100,000 Americans. [More]
Intervention program to help parents manage children's behaviors after being diagnosed with autism

Intervention program to help parents manage children's behaviors after being diagnosed with autism

In a first of its kind clinical trial, Debra Zand, Ph.D., and her team at Saint Louis University, will run an intervention program to help parents address and manage their children's challenging behaviors immediately after being diagnosed with autism. [More]
Study links gum disease to lung disease, cancer and heart failure

Study links gum disease to lung disease, cancer and heart failure

Most people are very familiar with the reality that, if they don't practice regular brushing and overall good dental hygiene, they are at risk for developing gum disease. Less well known is the full extent of the potential harm caused by gum disease. [More]
Regular blood transfusion therapy reduces recurrence of strokes in kids with sickle cell anemia

Regular blood transfusion therapy reduces recurrence of strokes in kids with sickle cell anemia

Vanderbilt-led research, as part of an international, multicenter trial, found regular blood transfusion therapy significantly reduces the recurrence of silent strokes and strokes in children with sickle cell anemia who have had pre-existing silent strokes, according to study results released today in the New England Journal of Medicine (NEJM). [More]
Study identifies protein that appears to play key role in protecting people infected with tuberculosis

Study identifies protein that appears to play key role in protecting people infected with tuberculosis

UCLA-led study has identified a protein that appears to play a key role in protecting people infected with Mycobacterium tuberculosis — the bacterium that causes tuberculosis — from developing the active form of the disease. [More]
FDA approves GlaxoSmithKline’s Arnuity Ellipta for treatment of asthma

FDA approves GlaxoSmithKline’s Arnuity Ellipta for treatment of asthma

GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older. Arnuity is not indicated for relief of acute bronchospasm. [More]